Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 17, 2011The Journal of Clinical Endocrinology & Metabolism

Pretreatment Serum Anti-Müllerian Hormone Predicts Long-Term Ovarian Function and Bone Mass after Chemotherapy for Early Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

RARichard A. AndersonBoston University
David Cameron
David CameronBrighton and Sussex Medical School

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Anderson et al. (2011) studied this question.

synapsesocial.com/papers/69dd40fcac7bdbc6c71013b3https://doi.org/10.1210/jc.2010-2582
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Human Ovarian Reserve from Conception to the Menopause2010 · 881 citations
  2. 2Ovary and ovulation: A model conforming the decline in follicle numbers to the age of menopause in women1996 · 422 citations
  3. 3Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.1997 · 266 citations
  4. 4Serum Anti-Müllerian Hormone Levels Reflect the Size of the Primordial Follicle Pool in Mice2006 · 384 citations
  5. 5The effects of radiotherapy and chemotherapy on female reproduction2001 · 885 citations